摘要
目的:通过分析探讨O6-甲基鸟嘌呤-DNA甲基转移酶(MGMT)基因启动子甲基化与MGMT蛋白表达的情况,以期为脑胶质瘤的临床个体化治疗提供一定的理论基础。方法:收集45例脑胶质瘤和11例正常脑组织石蜡标本,采用免疫组化方法分别检测MGMT在56例标本中的表达情况,采用甲基化特异性PCR(MSP)方法检测45例脑胶质瘤中MGMT基因启动子甲基化情况。结果:脑胶质瘤组织与正常脑组织中MGMT的表达差异有统计学意义。不同级别胶质瘤之间的MGMT表达差异无统计学意义。胶质瘤中MGMT的表达与患者的性别及年龄之间的差异无统计学意义。胶质瘤中MGMT蛋白表达与MGMT基因启动子甲基化存在负相关。不同级别脑胶质瘤中MGMT基因启动子甲基化的表达差异无统计学意义。结论:MGMT的表达与肿瘤的恶性程度无相关性,但与烷化剂耐药有关。临床上为患者制订个性化治疗方案时,不能单独考虑性别、年龄的因素。使用烷化剂化疗前测定肿瘤细胞的MGMT活性具有一定的指导意义。
OBJECTIVE： To explore the O^6-methylguanine DNA-methyltransferase （MGMT） gene promoter methylation and MGMT protein expression in order to provide a theoretical basis for clinical individualized treatment of glioma. METHODS： 45 glioma tissue paraffin specimens and 11 normal brain tissue paraffin specimens were collected for measurement of MGMT expression by immunohistochemical assay. MGMT gene promoter methylation in the 45 glioma specimens was detected by methylation specific PCR （MSP）. RESULTS： The expression of MGMT was statistically significant between gtioma tissue and normal brain tissue. MGMT expression level was not significantly different between the different grade of gliomas. MGMT expression was not associated with patient＇s sex and age differences. MGMT protein expression in gliomas was negatively associated with MGMT gene promoter methylation. MGMT gene promoter methylation was not associated with the grade of glioma. CONCLUSION： MGMT expression was not correlated with the degree of malignancy of tumor, but correlated with drug resistance of alkylating agents. In formulating individualized therapy for patients, clinicians should not consider the factors of gender and age alone. Measurement of MGMT activity in tumor cells before using alkylating chemotherapy is of guiding significance.
出处
《中国医院用药评价与分析》
2015年第4期466-468,475,共4页
Evaluation and Analysis of Drug-use in Hospitals of China
